TETRA BIO-PHARMA WKN: A2ASQ8 ISIN: CA88166Y1007 Kürzel: TBP Forum: Aktien Thema: Hauptdiskussion

Marktreife zum Beispiel. Vor 2022 passiert da nicht allzuviel. Covid zieht hier auch nicht wie bei ner Menge anderer. Die Tetra Aktionäre haben es lieber, wenn die alten Pläne eingehalten werden.

Fourtwenty, was muss denn passieren, dass sie nicht mehr klein gehalten wird?

✌️

Bis hier richtig was geht, dauert es noch n Weilchen

Tetra typischer Kursverlauf. Die Aktien wird seit Ewigkeiten künstlich klein gehalten.

Entspann dich Olli 😂

Rest Datei zerschossen, vielleicht später

Tetra’s Pipeline With each of Tetra’s drugs it’s important to note that they’re patent protected. It’s equally important to note that Tetra are years ahead of any competition and once their drugs are approved by the FDA, they’ll have “first to market” marketing exclusivity: ——————————————————————— PPP001 (QIXLEEF): this is Tetra’s tri-blend cannabis based drug mentioned above. This drug has been granted FDA legal “drug” jurisdiction - meaning the FDA will review this the same as any other pharmaceutical drug that has undergone studies and is seeking authorization. Originally, this drug was undergoing P3 studies in Canada, however in validating storage/ SOPs mycotoxins were detected and Tetra alerted Health Canada and suspended their study. This was quite a surprise as the cannabis for this drug was provided from Aphria and grown in a GMP compliant facility which highlights risks to patients. Tetra have always been adamant that patient safety is top priority and spent the last 6-8 months perfecting their SOPs to ensure a mycotoxin free / safe drug. They have recently been given the FDA green light to move forward with their P2 Plenitude Study. Given the Plenitude Study is aimed to alleviate pain in patients with advanced cancer, Tetra would be required to complete their P2 (n=78), and at which point they could initiate their NDA via accelerated approval / fast track pathway. Here, they’d obtain conditional marketing authorization with a commitment to conduct a post-marketing P4 confirmatory trial. It is my understanding that Tetra are in discussions with a potential partner(s) in the US to buy the licensing rights to this drug. Note: PPP001 was granted FDA orphan designation for complex regional pain syndrome. LINK: https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2019/FDA-Approves-Advancement-of-PPP001-Clinical-Trial-Previously-Discontinued/default.aspx LINK: https://www.globenewswire.com/news-release/2018/03/14/1482667/0/en/Tetra-Bio-Pharma-Announces-FDA-Orphan-Drug-Designation-for-PPP001-in-Treatment-of-Complex-Regional-Pain-Syndrome.html LINK: https://www.linkedin.com/pulse/tetras-week-turkey-green-light-from-fda-its-opioid-guy-chamberland

Für alle Neuen und interessierten.. Alle Infos aus einem wirklich sehr guten US-Forum zum Thema Tetra Bio

4 Millionen gehandelte gestern ist schon heftig, mal schauen was heute so geht

https://m.youtube.com/watch?feature=youtu.be&v=vJNrFSYF7k4

Interview mit Dr. Chamberland today

Bei anderen Firmen hätte man hier nach solchen Nachrichten schon mit gutem Geld rausgehen können. Hier wird der Kurs gedrückt oder was und warum auch immer.

https://www.google.de/amp/s/www.proactiveinvestors.com/companies/amp/news/924410

Tetra Bio-Pharma green lit by the FDA to proceed to a Phase 1 clinical study with coronavirus drug

Da ist schon was dran, aber es ist wieder Volumen drin und wohl die allerwenigsten, sind hier wohl im Plus 😉